Source comparison
BPC-157 Capsules vs Injection Bioavailability: Research Data Comparison
The table below compares measured bioavailability, pharmacokinetic parameters, and research considerations for oral versus subcutaneous BPC-157 delivery. Data derived from published pharmacokinetic studies and institutional research protocols. Oral Capsules (S
This comparison does not assign a generated winner or score.
- The table below compares measured bioavailability, pharmacokinetic parameters, and research considerations for oral versus subcutaneous BPC-157 delivery. Data derived from published pharmacokinetic studies and institutional research protocols.
- Oral Capsules (Standard)
- 15–30%
- 60–90 minutes
- 1.0× (baseline)
- Gastric pepsin hydrolysis + hepatic first-pass metabolism
- Useful for localized GI research only. Systemic effects unreliable
- Oral Capsules (Enteric-Coated)
- 20–35%
- 90–120 minutes
- 1.2–1.5×
- Intestinal proteases (trypsin, chymotrypsin) + hepatic clearance
- Marginal improvement. Still loses 65–80% of dose before circulation
- Subcutaneous Injection
- 85–95%
- 30–60 minutes
- 4.0–6.0×
- Minimal. Direct entry to systemic circulation
- Gold standard for research requiring systemic peptide exposure
- Intramuscular Injection
- 80–90%
- 20–40 minutes
- 3.5–5.5×
- Minimal. Faster diffusion than subcutaneous but shorter duration
- Faster absorption but less sustained plasma levels
- Oral capsules achieve approximately one-sixth the systemic exposure of subcutaneous injection when measured by AUC. Enteric coating helps, but the improvement is modest. 20–35% bioavailability is still inadequate for protocols designed around systemic peptide activity. Subcutaneous delivery consistently produces 85–95% bioavailability because the peptide never encounters the hostile enzymatic environment of the digestive tract. Intramuscular injection offers slightly faster absorption due to higher tissue vascularity but doesn't meaningfully change total bioavailability.
- One insight most comparisons miss: the variability in oral bioavailability is enormous. Individual differences in gastric pH, transit time, and hepatic enzyme activity mean that two subjects receiving identical oral doses can achieve 2–3× different plasma concentrations. Subcutaneous delivery is far more consistent. Absorption depends on injection technique and site selection, not gastrointestinal physiology.